The AECOM/AECC Data Safety monitoring plan establishes implementation plans for the policies set forth by the National Cancer Institute in the document entitled """"""""Policy of the National Cancer Institute for Data and Safety Monitoring of Clinical Trials"""""""" (http://cancertrials.nci.nih.gov/clinicaltrials/conductinq/dsm-auidelines/paae2V These policies pertain to the monitoring of all clinical trials supported by NCI, and thus encompass all NCI funded clinical trials, intramural, multicenter and cooperative group. The policies and procedures for Data and Safety Monitoring of the clinical research programs at the AECC are established and monitored by the Protocol Review and Monitoring Committee and the Cancer Center Clinical Research Executive Committee. The Data Safety Monitoring Committee is a major component of the Cancer Center and reports directly to the head of the Protocol Review and Monitoring Committee, the CPDMU, the Cancer Center Director and the AECOM/Montefiore IRBs. The document includes the major functions and responsibilities of data and safety monitoring of our active clinical trials program(s) and includes a detailed description of the following: Individual responsible for monitoring The frequency of the review A description of what is being monitored The procedures for different classes of clinical trials The evaluation and investigator feedback/communication process The procedures for managing and averting conflicts of interest Adverse event procedures Suspensions of clinical trials Protocol compliance auditing procedures The Data Safety Monitoring Committee (DSMC) has the responsibility for ensuring data and safety monitoring along with each of the protocol Principal Investigators who are ultimately responsible for the ongoing monitoring and safety of clinical protocols. The DSMC is comprised of investigators from throughout the College and Cancer Center, and have a variety of different expertise. Dr. Richard Gorlick chairs the DSMC. The remainder of the membership is listed in the table below. The DSMC is provided with administrative support, database management, etc., by the CPDMU. The DSMC meeting occurs immediately prior to the PRMC meeting to ensure immediate transmission of information. Representatives of the CCI and PRMC serve in a non-voting capacity on the DSMC to assure communication.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013330-40
Application #
8582107
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-01
Project End
2018-06-30
Budget Start
2013-08-23
Budget End
2014-06-30
Support Year
40
Fiscal Year
2013
Total Cost
$169,185
Indirect Cost
$51,766
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Agalliu, Ilir; Chen, Zigui; Wang, Tao et al. (2018) Oral Alpha, Beta, and Gamma HPV Types and Risk of Incident Esophageal Cancer. Cancer Epidemiol Biomarkers Prev 27:1168-1175
Bhargava, Ragini; Sandhu, Manbir; Muk, Sanychen et al. (2018) C-NHEJ without indels is robust and requires synergistic function of distinct XLF domains. Nat Commun 9:2484
Collu, Giovanna M; Jenny, Andreas; Gaengel, Konstantin et al. (2018) Prickle is phosphorylated by Nemo and targeted for degradation to maintain Prickle/Spiny-legs isoform balance during planar cell polarity establishment. PLoS Genet 14:e1007391
Doyle, Christopher R; Moon, Jee-Young; Daily, Johanna P et al. (2018) A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice. Infect Immun 86:
Anayannis, Nicole V; Schlecht, Nicolas F; Ben-Dayan, Miriam et al. (2018) Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma. PLoS One 13:e0191581
Stepankova, Martina; Bartonkova, Iveta; Jiskrova, Eva et al. (2018) Methylindoles and Methoxyindoles are Agonists and Antagonists of Human Aryl Hydrocarbon Receptor. Mol Pharmacol 93:631-644
Maggi, Elaine C; Gravina, Silvia; Cheng, Haiying et al. (2018) Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model. Front Genet 9:6
Ingram, Jessica R; Blomberg, Olga S; Rashidian, Mohammad et al. (2018) Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A 115:3912-3917
Dulyaninova, Natalya G; Ruiz, Penelope D; Gamble, Matthew J et al. (2018) S100A4 regulates macrophage invasion by distinct myosin-dependent and myosin-independent mechanisms. Mol Biol Cell 29:632-642
Chen, Zigui; Schiffman, Mark; Herrero, Rolando et al. (2018) Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology 516:86-101

Showing the most recent 10 out of 1508 publications